28133468|t|Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination.
28133468|a|Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) since it incorporates the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. Neprilysin is an endopeptidase that breaks down several vasoactive peptides including natriuretic peptides (NPs), bradykinin, endothelin and angiotensin II (Ang-II). Therefore, a natural consequence of its inhibition is an increase of plasmatic levels of both, NPs and Ang-II (with opposite biological actions). So, a combined inhibition of these both systems (Sacubitril / valsartan) may enhance the benefits of NPs effects in HF (natriuresis, diuresis, etc) while Ang-II receptor is inhibited (reducing vasoconstriction and aldosterone release). In a large clinical trial (PARADIGM-HF with 8442 patients), this new agent was found to significantly reduce cardiovascular and all cause mortality as well as hospitalizations due to HF (compared to enalapril). This manuscript reviews clinical evidence for sacubitril valsartan, dosing and cautions, future directions and its considered place in the therapy of HF with reduced ejection fraction.
28133468	26	39	heart failure	Disease	MESH:D006333
28133468	88	98	sacubitril	Chemical	MESH:C000717211
28133468	99	108	valsartan	Chemical	MESH:D000068756
28133468	164	172	patients	Species	9606
28133468	186	199	heart failure	Disease	MESH:D006333
28133468	201	203	HF	Disease	MESH:D006333
28133468	253	273	Sacubitril valsartan	Chemical	MESH:C549068
28133468	295	301	LCZ696	Chemical	MESH:C549068
28133468	373	386	heart failure	Disease	MESH:D006333
28133468	542	552	neprilysin	Gene	4311
28133468	564	574	sacubitril	Chemical	MESH:C000717211
28133468	619	628	valsartan	Chemical	MESH:D000068756
28133468	630	640	Neprilysin	Gene	4311
28133468	716	736	natriuretic peptides	Chemical	MESH:D045265
28133468	738	741	NPs	Chemical	MESH:D045265
28133468	744	754	bradykinin	Gene	3827
28133468	771	785	angiotensin II	Gene	183
28133468	787	793	Ang-II	Gene	183
28133468	891	894	NPs	Chemical	MESH:D045265
28133468	899	905	Ang-II	Gene	183
28133468	991	1001	Sacubitril	Chemical	MESH:C000717211
28133468	1004	1013	valsartan	Chemical	MESH:D000068756
28133468	1043	1046	NPs	Chemical	MESH:D045265
28133468	1058	1060	HF	Disease	MESH:D006333
28133468	1156	1167	aldosterone	Chemical	MESH:D000450
28133468	1214	1216	HF	Disease	MESH:D006333
28133468	1227	1235	patients	Species	9606
28133468	1361	1363	HF	Disease	MESH:D006333
28133468	1377	1386	enalapril	Chemical	MESH:D004656
28133468	1435	1455	sacubitril valsartan	Chemical	MESH:C549068
28133468	1539	1541	HF	Disease	MESH:D006333
28133468	Negative_Correlation	MESH:C000717211	4311
28133468	Positive_Correlation	MESH:D000068756	MESH:D045265
28133468	Negative_Correlation	MESH:D004656	MESH:D006333
28133468	Negative_Correlation	MESH:C000717211	183
28133468	Negative_Correlation	MESH:D000068756	MESH:D006333
28133468	Negative_Correlation	183	4311
28133468	Negative_Correlation	3827	4311
28133468	Negative_Correlation	MESH:C000717211	MESH:D006333
28133468	Negative_Correlation	MESH:C549068	4311
28133468	Negative_Correlation	MESH:C000717211	MESH:D045265
28133468	Negative_Correlation	MESH:D000068756	183
28133468	Negative_Correlation	MESH:C549068	MESH:D006333
28133468	Association	MESH:D045265	4311
28133468	Comparison	MESH:C000717211	MESH:D000068756

